GlassScriptPhysician profile
Amitra Caines
NPI 1477621019
$3,833.09
in general payments reported to CMS, 2019-2025
32 companies · $785 in 2025
The $785 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2021: $477 · 2022: $465 · 2023: $1,193 · 2024: $640 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,618.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $454.57 | 2021-2025 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $402.95 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $379.99 | 2021-2025 | Verquvo |
| Pfizer INC. | $336.54 | 2019-2025 | |
| Amgen INC. | $232.78 | 2021-2025 | Repatha, Repatha |
| Kestra Medical Technology Services, INC. | $230.30 | 2023-2024 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $227.71 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $200.85 | 2021-2024 | Xarelto |
| Abbott Laboratories | $181.63 | 2023-2025 | Gallant, Aveir |
| Novo Nordisk INC | $154.35 | 2023-2025 | Ozempic, Wegovy |
| Cvrx, INC. | $129.13 | 2023-2025 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $124.05 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $89.40 | 2023-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $63.09 | 2022-2023 | Lifevest |
| Abiomed | $62.29 | 2023-2025 | Impella |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $54.86 | 2023 | Inpefa |
| Alnylam Pharmaceuticals INC. | $53.47 | 2023-2025 | Onpattro, Amvuttra |
| Boston Scientific Corporation | $50.70 | 2021-2025 | Cds - Mct/Cem Monitoring |
| Esperion Therapeutics, INC. | $49.13 | 2021 | |
| Amarin Pharma, INC. | $41.70 | 2021-2022 | |
| Bardy Diagnostics, INC. | $40.00 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $31.27 | 2025 | Uptravi |
| Irhythm Technologies, INC. | $30.60 | 2023 | Zio Xt Patch |
| Janssen Biotech, INC. | $30.29 | 2023 | Stelara |
| Scpharmaceuticals INC. | $27.73 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.57 | 2025 | |
| Angiodynamics, INC. | $27.25 | 2022 | |
| Arbor Pharmaceuticals, INC. | $26.09 | 2021 | |
| Cardiovascular Systems INC. | $24.61 | 2019 | |
| Glaxosmithkline, LLC. | $18.36 | 2025 | Shingrix, Arexvy |
| Philips North America LLC | $15.41 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Bard Peripheral Vascular, INC. | $14.42 | 2025 | Venclose Maven Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amitra Caines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.